Merck KGaA Drops Lipoprotein(a) Heart Drug After Novartis Trial Failure, Leaving Fewer Drugs in Testing for High Lp(a)
Merck KGaA will not advance its experimental Lp(a)-lowering drug, zerlasiran, after Novartis' similar drug failed to prevent heart attacks or strokes. The decision follows a phase 2 trial where zerlasiran reduced Lp(a) by 80%. Merck is acquiring zerlasiran through its planned purchase of Silence Therapeutics for $1.3 billion. The setback raises doubts about Lp(a)-lowering drugs, with other companies like Amgen and Eli Lilly still testing their candidates.
How this was made

The 30-second read
Why it matters
The decision highlights doubts about the Lp(a) therapeutic approach and could pressure other developers in the space.
Market read
The news may cause short‑term weakness in Merck KGaA and peer biotech stocks focused on Lp(a) therapies.
What to watch
Merck KGaA may redirect resources to other pipelines, mitigating long‑term risk.
Background
Merck KGaA announced it will not advance its Lp(a)-lowering drug zerlasiran into late‑stage trials after a recent negative outcome for a similar Novartis drug.
Market effects
Potential slowdown in Lp(a) therapeutic pipeline may affect biotech sector sentiment.
European biotech stocks could see modest pressure.
Limited global impact; mainly relevant to investors in cardiovascular drug developers.
Counterpoint
Some investors may view the setback as a buying opportunity if the market overreacts.
Key entities
- companyMerck KGaA
German pharmaceutical company halting development of zerlasiran.
- companySilence Therapeutics
Target of Merck's acquisition, owner of zerlasiran.
- companyNovartis
Developer of pelacarsen, whose trial failure prompted Merck's decision.


